Kornimate/medical-research-clean huggingface dataset:
comparing 18f-fapi-04 and 18f-fdg pet/ct in cancer detection

Conditions: Malignant Neoplasm

Summary: evaluating fluoro-18-fibroblast activation protein inhibitor-04 positron emission computed tomography's diagnostic efficacy for primary malignancies versus 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose.

in recent years, radionuclide labeled fibroblast activating protein inhibitors (fapis) have gradually become a new strategy for targeted diagnosis and therapy. in this study, radionuclide 18f was used to label fapi, and the imaging value of fapi was compared with that of common developer 18f-fdg. to evaluate the diagnostic value of 18f-fapi-04 pet/ct in various malignant tumors.

Eligibility criteria:
inclusion criteria: adult (≥18 years old); pet/ct examination is required after evaluation by oncologist. healthy persons who volunteer for pet/ct scans; can cooperate to complete the inspection process; i or family members, legal representatives agree to participate in the study and can sign the informed consent in person. exclusion criteria: the patient has a serious underlying disease or mental illness and is unable to cooperate with the pet/ct examination; have received systematic chemotherapy; previous history of primary tumor; pregnancy; i or family members, legal representatives are unable or unwilling to provide written informed consent.

Keywords: 18f-fdg 18f-fapi pet/ct
characterization of the fungal immunopeptidome involved in the immunopathological mechanisms of psoriasis

Conditions: Psoriasis

Summary: psoriasis is a chronic immune-mediated skin disorder characterized by inflammatory cutaneous plaques and, occasionally, arthritis, affecting 60 million adults and children worldwide. although a variety of treatments have been developed aimed to relieve the associated symptoms, there is yet no permanent cure for psoriasis. th17 type immunity, via the production of il-17a and other pro-inflammatory cytokines, are considered to play a central role in the pathogenesis of this disease. moreover, experimental evidence obtained in animal models, points to human mycobiota as a trigger for the initiation and/or progression of psoriasis. therefore, human studies are required to better characterize the major fungi implicated in the local and systemic inflammatory responses, as well as to determine the immunopeptidome that shapes the pathogenic t cell receptor repertoire. we will explore the hypothesis that commensal fungi could participate in the chronic inflammatory immune response underlying the pathogenesis of human psoriasis via the recognition of cutaneous fungal antigens and/or via a gut-skin mycobiome cross-reactive mechanism

the overall aim of the project is : i) to characterize the nature of human local and systemic inflammatory responses against commensal skin and gut fungal species in psoriatic patients (psop) and ii) to determine the fungal immunopeptidome that contributes to the shaping of the t cell receptor (tcr) repertoire of skin-infiltrating t cells. the project is divided into four major scientific objectives: 1. to determine the mycobiome profiles in healthy donors (hd) and psop. 2. to characterize the contribution of mycobiota to the local cutaneous cd4+ t cell response. 3. to assess systemic the cd4+ t cell-fungal cross-reactivity. 4. to establish the immunopeptidome of the major cd4+ t cell-reactive fungus enabling the development of an innovative immunotherapy.

Eligibility criteria:
inclusion criteria: adults with psoriasis failing local treatment. adults requiring reconstructive plastic surgery (resident skin immunology checks). adults living in the same household as a patient suffering from psoriasis (intestinal mycobiome checks). exclusion criteria: minors individuals under legal protection. pregnant or breastfeeding women

Keywords: fungi immunopeptidome psoriasis il17
the development of diagnosis and prognosis predictive model for peripheral nerve disease

Conditions: Peripheral Nerve Disease

Summary: this is a retrospective observational cohort study (mrn-pnd), aiming to explore the utility of contrast-enhanced mrn (cemrn) compared to plain mrn in diagnosing peripheral nerve diseases and predicting the prognosis of patients with these conditions. additionally, artificial intelligence (ai) methods are employed to enhance the diagnostic accuracy of mrn for peripheral nerve diseases and to precisely predict disease outcomes.


Eligibility criteria:
inclusion criteria: 1. patients who underwent mrn scanning at wuhan union hospital between january 2015 and january 2025; 2. age \> 18 years; 3. definitive clinical diagnosis (either healthy individuals or patients with a specific condition). exclusion criteria： 1. poor quality of imaging; 2. incomplete clinical data or loss to follow-up; 3. unclear clinical diagnosis.
effects of combined metformin and cabergoline in comparison with metformin only therapy on ovarian and hormonal activities in iraqi patients with pcos

Conditions: Polycystic Ovary Syndrome

Summary: the goal of this interventional randomized clinical is to compare the effect of metformin alone, cabergoline alone and metformin and cabergoline in combination in a sample of iraqi female patients with polycystic ovary syndrome. the main questions to answer are: 1. what are the effects of the tested regimens on body mass index (bmi)? 2. what are the effects of the tested regimens on hormonal status? 3. what are the effects of the tested regimens on uterine artery resistive index ? 4. what are the effects of the tested regimens on some inflammatory markers? participants will be separated into two groups: 1. group 1 (m): 25 patients, received metformin 500mg per oral twice daily for 90 days duration. 2. group 2 (d): 25 patients, received dostinex (pergolin) 0.5 mg per oral (single dose per/week). 3. group 3 (md): 25 pateins, received metformin 500 mg per oral twice daily for 90 days duration and dostinex (pergolin) as 0.5 mg per oral (single dose per/week). researchers will compare group 1 (m), group 2 (d), group 3 (md) to observe the effect of the tested treatment regimens on body mass index, hormonal status, uterine artery resistive index, and some inflammatory markers that are il-18, anti-gad antibody and gnrh antibody.


Eligibility criteria:
inclusion criteria: * age 18 - 40 years * diagnosed with polycystic ovarian syndrome based on rotterdam criteria * body mass index (bmi) \< 40 kg/m² exclusion criteria: * age less than 18 years or more than 40 years * co-morbid conditions including (diabetes mellitus, essential hypertension, and thyroid disease) * patients planning for conception. * body mass index \> 40 kg/m²

Keywords: polycystic ovary syndrom hormones endometrial resistive index metformin cabergoline
a phase ii clinical study of hrs-7058 in combination with antitumor drugs in patients with advanced malignant tumour

Conditions: Advanced Malignant Tumour

Summary: this study is a multicentre, open phase ii clinical study of dose escalation, dose extension and efficacy extension of hrs-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. to evaluate the safety, tolerability and efficacy of hrs-7058 in combination with antitumor drugs.


Eligibility criteria:
inclusion criteria: 1. the subjects gave informed consent to the study before participating in, and voluntarily signed informed consent; 2. 18 to 75 years old (including both ends), gender is not limited; 3. subjects with unresectable locally advanced or metastatic solid tumour confirmed by histopathology; 4. having at least one evaluable or measurable lesion according to the solid tumour response evaluation criteria (recist 1.1); 5. ecog performance status of 0 or 1; 6. the expected survival time is more than 12 weeks; 7. be able to ingest drugs and be able to comply with trial and follow-up procedures; 8. adequate bone marrow and organ function; 9. female subjects of childbearing potential must undergo a serum pregnancy test within 7 days before the first administration of the study drug, and the result must be negative; and they must not be lactating. female subjects of childbearing potential and male subjects whose partners are females of childbearing potential must agree to comply with contraceptive requirements from the time of signing the informed consent form until 5 months after the last administration of the study drug (for male subjects) or 8 months after the last administration of the study drug (for female subjects). exclusion criteria: 1. accompanied by untreated or active central nervous system (cns) tumour metastasis; 2. antitumor therapy within 28 days prior to initial use of the investigational drug; 3. the adverse reactions of previous anti-tumour therapy have not recovered to ctcae ≤ grade 1; 4. with known or suspected interstitial pneumonia; 5. with severe cardiovascular and cerebrovascular disease 6. had other malignancies within five years prior to first use of the investigational drug; 7. severe infection within 28 days prior to first use of the investigational drug; 8. history of immune deficiency; 9. refractory nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications; 10. the presence of uncontrolled pleural, abdominal or pericardial effusion; 11. had undergone major organ surgery within 28 days prior to the first use of the study drug; 12. women during pregnancy or lactation; 13. known allergies and contraindications to the investigational drug or any of its components; 14. according to the judgment of the investigator, there are any other circumstances that may increase the risks of participating in the study, interfere with the study results, or make the subjects unsuitable for participating in this study.
physical abilities of teenagers with familial mediterranean fever

Conditions: Familial Mediterranean Fever

Summary: physical abilities of teenagers with familial mediterranean fever

physical abilities of teenagers with familial mediterranean fever by describing the maximum oxygen consumption (vo2max) estimated from a 6-minute walk test

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of fmf according to the tel-hashomer criteria for whom a sports evaluation was offered during their bridging program * age \>12 * followed or having been followed in the pediatric department of the ch of versailles * no opposition of the patient and his/her parent/legal guardian in case of a minor patient exclusion criteria: expressed refusal of the patient and his/her parent/legal guardian to participate in the study and/or to use genetic data for research purposes
assessing everolimus in fist line treatment on patients with metastatic kidney cancer

Conditions: Kidney Cancer

Summary: it is a an open label, multicentric, phase ii study assessing the efficacy of everolimus (given per os) as a first line treatment in kidney cancer of bad prognosis. 92 patients will be included (anticipated). the treatment by everolimus will continue until progression, significant toxicity or withdraw of consent


Eligibility criteria:
inclusion criteria: 1. metastatic kidney cancer, regardless of histology (except bellini carcinomas), with measurable or evaluable disease 2. age \>= 18 years 3. with karnofsky ≥ 60 4. without prior treatment for metastatic cancer (chemotherapy, targeted therapy, or mtor inhibitor) 5. bad prognosis, defined as follows: at least three of the following six criteria of poor prognosis: * karnofsky \<80 * ldh\> 1.5 uln * hemoglobin \<lln * corrected calcium\> 2.5 mmol / l (10 mg / dl) * time frame between initial diagnostic and treatment \<1 year * more than one metastatic site 6. medullary function: neutrophils ≥ 1.5 x 109 / l, platelets ≥ 100 x 109 / l, hb\> 8g/dl 7. hepatic function: bilirubin: ≤ 1.5 x uln, alt and ast ≤ 2.5x uln in the absence of hepatic metastasis ≤ 5x uln if hepatic metastasis documented 8. renal function: creatinine \<1.5 x uln 9. life expectancy\> 3 months, 10. patient signed informed consent and agreeing to comply with the requirements of the trial exclusion criteria: 1. previous treatment with chemotherapy, targeted therapy, or mtor inhibitor 2. previous radiotherapy in the last 2 weeks 3. chronic treatment with corticoids or immunosuppressive agents except substitutive opotherapy.. a washout period of at least 8 days must be respected before the patient inclusion. 4. patients with brain metastases untreated or uncontrolled by prior treatment. the non-progression of the metastases must be proved by comparing two brain scans separated by a minimum interval of 6 weeks. 5. active bleeding 6. patient with positive serology hbs (ag hbs (+) and ac anti-hbc (+) 7. hypersensitivity to everolimus, sirolimus, to other rapamycin derivatives or to any of the excipients 8. severe or uncontrolled medical pathology: * unstable angina, symptomatic heart failure, myocardial infarction ≤ 6 months before randomization, severe rhythm disorder, * uncontrolled diabetes with glycaemia\> 1.5x uln. * active or uncontrolled infection. * cirrhosis or chronic active hepatitis, * severe alteration in lung function (\> 50% decrease in fev or vital capacity) 9. other cancer within the past 3 years, with the exception of basal cell carcinoma and carcinoma in situ of the cervix 10. pregnant or lactating woman, and adults refusing an effective contraceptive method 11. participation in another clinical trial with an investigational drug 12. refusal of the patient to comply with the rules of the clinical trial 13. person deprived of liberty or person under guardianship, inability to submit to medical treatment test for geographical, social or psychological reasons.
efficacy and safety of k-rod dynamic stabilization system in the repair of lumbar degenerative diseases

Conditions: Intervertebral Disk Degeneration

Summary: to conduct a prospective, single-center, self-controlled, clinical trial to verify the efficacy and safety of k-rod dynamic stability system in the repair of lumbar degenerative diseases following 2 years follow-up, aiming to provide references for clinical treatment of lumbar degenerative diseases.

posterior internal fixation and fusion systems are still one of the main methods for the treatment of chronic back pain due to intervertebral disc degeneration, but adverse reactions, such as accelerated regression of adjacent segments, are often inevitable during the treatment. at present, various pedicle screw-based posterior dynamic stability systems of the lumbar spine have become an alternative fusion therapy for lumbar degenerative diseases. dynamic stability is defined to reduce the loading on the intervertebral disc/articular surfaces, to maintain movement under mechanical load, to limit the abnormal movement of the spinal segment, and to reduce the stress on the bone-screw interface dynamically and stably. an ideal fixation system will be stable enough to maximize the fusion rate without the need for excessive rigidity, as well as to maintain maximum load and physiological posture of the vertebral segment, thereby reducing the horizontal stress of the adjacent segment.

Eligibility criteria:
inclusion criteria: * degenerative lumbar spondylolisthesis (degree i) * nerve root canal or central spinal canal stenosis * accompanying nerve root pain and/or chronic back pain * 32-76 years old * regardless of gender * all patients or family members signed the informed consent exclusion criteria: * systemic infection; * poor compliance and inability to complete the trial
safety and efficacy study of ai lvef

Conditions: Heart Failure, Systolic; Heart Failure, Diastolic

Summary: to determine whether an integrated ai decision support can save time and improve accuracy of assessment of echocardiograms, the investigators are conducting a blinded, randomized controlled study of ai guided measurements of left ventricular ejection fraction compared to sonographer measurements in preliminary readings of echocardiograms.


Eligibility criteria:
inclusion criteria: * the study imaging studies will include patients who underwent imaging (limited or comprehensive transthoracic echocardiogram studies) and a lvef was adjudicated in the echocardiography/non-invasive cardiac imaging laboratory. * the study participants are cardiologists reading in the echocardiography/non-invasive cardiac imaging laboratory. exclusion criteria: * the study imaging studies will exclude transesophageal echocardiogram imaging. * the study will exclude cardiologists who decline to participate

Keywords: echocardiogram artificial intelligence
comparative trial of oral penicillin versus cefuroxim for treatment of perianal streptococcal dermatitis

Conditions: Streptococcal Infections

Summary: the goal of the study is to investigate, which of two antibiotic treatments - oral penicillin for 10 days or oral cefuroxim for 7 days - is more successful for patients (1-16 years of age) with perianal dermatitis caused by group a beta-hemolytic streptococci.

the goal of the study is to investigate, which of two antibiotic treatments - oral penicillin for 10 days or oral cefuroxim for 7 days - is more successful for patients (1-16 years of age) with perianal dermatitis caused by group a beta-hemolytic streptococci (gabhs). diagnosis is based on positive perianal culture for gabhs. informed consent will be obtained. the study will be performed in the region of basel, switzerland, in private practices of pediatricians, general practitioners, and selected pediatric dermatologists as well as in the out-patient departments of the university children's hospital basel and the department for dermatology of the university of basel. patients (or their parents) will fill in a daily diary on signs and symptoms of disease; furthermore, clinical investigations (inspection of the site of infection) will be performed on enrollment (day 1), day 3, and at the end of treatment (day 10).

Eligibility criteria:
inclusion criteria: * informed consent * age 1-16 years * typical clinical symptoms for perianal dermatitis * positive perianal culture for gabhs exclusion criteria: * antibiotic treatment in previous 14 days * immunodeficiency * penicillin allergy * cephalosporin allergy * further bacterial infections

Keywords: perianal dermatitis streptococcus pyogenes
echocardiography in kids intensive care decision support

Conditions: Fluid Responsiveness; Cardiac Output

Summary: a study to determine if echocardiographically derived parameters, plethysmographic variability index and pulse pressure variation predict fluid responsiveness in children on picu.

a study to determine if echocardiographically derived parameters, plethysmographic variability index and pulse pressure variation predict fluid responsiveness in children on picu. these parameters will be measured pre and post fluid bolus in children prescribed fluid bolus therapy for clinical indications on the picu. children will be classified as responders (\>10% increase in cardiac output) and non responders (\<10% increase). appropriate statistical tests will be performed to determine the most useful predictor of an increase in cardiac output following a fluid bolus.

Eligibility criteria:
inclusion criteria: * any ventilated child requiring fluid bolus therapy on the picu for clinical indications exclusion criteria: * arrythmia * intracardiac shunt

Keywords: shock fluid bolus cardiac output children in intensive care
comparative effects of acbt and bubble positive expiratory pressure device in asthmatic patients

Conditions: Asthma

Summary: the study gap is that in previous studies the effects of bubble-pep in different diseases have been studied but it's never been studied in asthmatic patients, so the reason behind this study is to see effects of bubble-pep in asthmatic patients.

the aim of this study was to determine the effect of bubble-pep device compared to acbt in asthmatic patients. this study will be randomized clinical trial, subject diagnosed with asthma meeting predetermined inclusion and exclusion criteria and will be divided into two groups. the baseline treatment for both groups would be diaphragmatic breathing exercises. while group a will be treated with acbt and group b will be treated with bubble-pep device. each subject will receive 18 sessions with 3 treatments per week. post treatment values will be recorded after the session and recorded values will be analyzed using spss 25

Eligibility criteria:
inclusion criteria: * aged between 31 to 40 years * male \& female * mild asthmatic patients * able to perform techniques * those who have never taken therapies for asthma before. * chronic asthma exclusion criteria: * patients with hypertension * cardiac diseases * any rib fracture * previously taken instructions regarding this. * any other unstable medical conditions

Keywords: asthma active cycle breathing technique bubble pep
impact of a chewable plant sterol supplement on ldl-c in a real-world setting

Conditions: Hyperlipidemia

Summary: the purpose of this study is to measure the effectiveness of a twice daily plant sterol supplement, which is in a gummy format and packaged with health insights, in reducing ldl-c cholesterol in a real word setting.

while the safety and benefits of plant sterol supplements have been established and are incorporated into many lipid lowering guidelines, there have been few prior studies of plant sterol chewables in gummy format among real world subjects. in this study, we aim to measure the ldl-c reducing impact of regular plant sterol supplementation in a real world setting.

Eligibility criteria:
inclusion criteria: 1. subject is an adult ≥18 years of age who continuously used the sponsor's product for at least 10 weeks prior to the follow-on lipid test 2. baseline lipid test conducted within past 2 years 3. if smoker, smoking status or frequency has not changed between two lipid test dates 4. subject understands the study procedures and signs forms documenting informed consent exclusion criteria: 1. subject was taking a prescription cholesterol-lowering medication or taking dietary supplements for cholesterol-lowering such as red yeast rice, niacin or omega-3 fatty acid supplements at the time of either lipid test 2. subject does not read english
postpartum depression in the covid-19 pandemic and the impact of anaesthesia

Conditions: Postpartum Depression; Psychological Stress; Maternal Distress

Summary: the aim of this multicenter prospective study is to evaluate the association between the covid-19 pandemic maternal psychological distress with the postpartum depression, demographic and anaesthesiologic variables


Eligibility criteria:
inclusion criteria: * all pregnant women over the age of 18 that present for labour (vaginal delivery or caesarean section) exclusion criteria: * not eligible in writing and reading in greek * drug abuse

Keywords: postpartum depression covid-19 pandemic anaesthesia